Tumor-treating fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy.

We found that treatment with TTFields or anti-PD-1 alone had no effect on the frequency of CD8+ and CD4+TILs, while treatment with TTFields plus anti-PD-1 showed a trend toward an increased number of these cells, but this varied between experiments and did not reach statistical significance (Fig. 5 i–k).

also in 53,322 other papers